JOINN LABORATORIES(CHINA)CO.,LTD. Joinn Laboratories(China)Co.,Ltd. Stock
Equities
603127
CNE100002W27
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.78 CNY | -3.95% |
|
-8.56% | -29.23% |
| Sales 2024 * | 2.41B 333M | Sales 2025 * | 2.88B 398M | Capitalization | 11.57B 1.6B |
|---|---|---|---|---|---|
| Net income 2024 * | 514M 71M | Net income 2025 * | 673M 92.96M | EV / Sales 2024 * | 3.42 x |
| Net cash position 2024 * | 3.32B 459M | Net cash position 2025 * | 3.68B 508M | EV / Sales 2025 * | 2.74 x |
| P/E ratio 2024 * |
24.5
x | P/E ratio 2025 * |
18.7
x | Employees | 2,510 |
| Yield 2024 * |
1.01% | Yield 2025 * |
1.19% | Free-Float | 58.77% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.95% | ||
| 1 week | -8.56% | ||
| Current month | -7.19% | ||
| 1 month | -15.97% | ||
| 3 months | -18.19% | ||
| 6 months | -34.86% | ||
| Current year | -29.23% |
1 week
16.58
18.32
1 month
16.5820.01
Current year
13.8023.73
1 year
13.8039.14
3 years
13.8092.87
5 years
10.6792.87
10 years
2.3992.87
| Managers | Title | Age | Since |
|---|---|---|---|
Da Peng Gao
CEO | Chief Executive Officer | 42 | 12-10-31 |
Ai Shui Yu
DFI | Director of Finance/CFO | 48 | 19-06-30 |
Ye Li
CHM | Chairman | 42 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yu Xia Feng
FOU | Founder | 60 | 95-08-10 |
Cong Lin Zuo
BRD | Director/Board Member | 60 | 96-11-30 |
Yun Xia Sun
BRD | Director/Board Member | 56 | 99-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.46% | 2 M€ | -20.87% | - | |
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 16.78 | -3.95% | 12,579,970 |
| 24-04-18 | 17.47 | -1.63% | 13,845,040 |
| 24-04-17 | 17.76 | +6.86% | 20,713,330 |
| 24-04-16 | 16.62 | -6.52% | 17,685,680 |
| 24-04-15 | 17.78 | -3.11% | 14,714,160 |
End-of-day quote Shanghai S.E., April 18, 2024
More quotes
Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
16.78
CNY
Average target price
19.29
CNY
Spread / Average Target
+14.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.23% | 1.66B | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- 603127 Stock
